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Abstract:
The chick separation stress paradigm has been validated as an anxiolytic screening assay.
However, whether the paradigm better models Panic Disorder(PD)or Generalized
Anxiety Disorder(GAD)is unknown. To pharmacologically dissociate the chick
separation stress paradigm as a model ofPD or GAD,subjects were administered drug
probes that were either: 1) only effective in the treatment ofPD (phenelzine 3.125-25.0
mg/kg), 2) effective in the treatment of both PD and GAD (alprazolam 0.065-0.5 mg/kg;
clonidine 0.1-0.25 mg/kg; imipramine 1.0-15.0mg/kg), 3)only effective in the treatment
of GAD (buspirone 2.5-10.0 mg/kg; trazodone 0.1-3.0 mg/kg), or 4)capable of
exacerbating symptoms ofPD in humans(yohimbine 0.1-3.0 mg/kg). At 7-days post
hatch, chicks received either vehicle or drug probe intramuscular 15 min prior to social
separation under a Mirror (low-stress) or No-Mirror (high-stress) condition for a 180 sec
observation period. Dependent measures were distress vocalizations to index separation
stress and sleep onset latency to index sedation. Phenelzine, alprazolam, imipramine, and
clonidine showed significant anxiolytic effects at doses without significant sedation in the
model, while buspirone and trazodone did not show significant anxiolytic effects.
Paradoxically, yohimbine produced modest anxiolytic effects. These results suggest the
chick separation stress paradigm better models PD than GAD as an anxiolytic screen.
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Introduction

The US philosopher William Barrett once wrote,“Anxiety is not fear, being afraid
of this or that definite object, but the uncanny feeling of being afraid of nothing at all. It
is precisely Nothingness that makes itself present and felt as the object of our dread.”
Everyone will experience symptoms of anxiety at some point in their lives. These
symptoms become a problem, however, once they become repetitive, intrusive and
associated with inappropriate thoughts or actions(Pincus 1995). There are 40 million
(18.1% of adults within a given year) adults who suffer from an anxiety disorder, which
makes it the most prevalent mental disorder in the US (Kessler 2005). These disorders
are largely treatable with current medications. However, a problem arises when trying to
find novel drugs which reduce anxiety effectively without the side-effects and
dependency issues of the current medications (Willner 1991). Essentially, this problem
hinges on the much greater dilemma of dealing with animal models used in the screening
of novel drugs.
Animals have long been utilized as research subjects in the hopes of modeling
some aspect of human behavior. However, the term model is hard to define since it is
extremely difficult to replicate a particular human behavior in another species. One allencompassing definition of“animal model” does not exist. It is, therefore, more precise
to categorize animal models into three specific classifications, each with its own
definition (Willner 1991).
The first classification is behavioral bioassays. These assays serve to model a
total physiological action. The entire animal serves as a measuring device to determine
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the functional state of a physiological system, similar to how the same measurement
might be made in an isolated tissue or test tube. In large part, behavioral bioassays are
used to study mechanisms responsible for changes in brain function, typically those
resulting from chronic drug administration or brain lesions(Willner 1991). Therefore,
although behavioral bioassays are valuable tools in the study of anxiety, the research of
this laboratory is primarily focused on the second two categories.
The second classification is animal models used as a screening test, which serves
to model a drug action. In short,‘The search for novel psychotropic agents is based upon
the action of known drugs, which serve as reference points against which to compare the
performance of new candidates”(Willner 1991). In order to determine a novel drug
compound,two forms of screening procedures exist. The first is to identify compounds
likely to have a specific type of clinical action. This allows for the identification of
clinically effective drugs that vary widely in the chemical structure. The second strategy
for screening tests is to identify specific biochemical actions as targets for drug
development. One drawback to this procedure is that it can only be accomplished once
the specific mode of action of existing compounds has been established, which in many
cases is not a feasible option. Also, the second strategy has the major disadvantage of
inhibiting the discovery of chemically novel modes oftreatment(Willner 1991).
According to Willner, “Irrespective of the manner in which they are constructed,
screening tests are subject primarily to one very simple requirement: the test should
predict accurately the desired activity, it should accept drugs that are effective and reject
those that are ineffective.”
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Also relevant to this study is the third category of animal models,those used as a
model of human behavior or simulation. Although this category includes models of all
forms of animal behavior, this study will focus on simulations ofabnormal behavior. The
purpose of these models is to simulate a symptom, or group ofsymptoms, of a particular
disorder. Methods of constructing the simulation vary greatly; they include brain
damage, selective breeding, selection ofextreme individuals, and the application of a
variety of factors assumed to be implicated in the etiology of mental disorders such as
stressors, social isolation, or aging. The object ofthese manipulations is to produce a
behavioral state that can be used as a tool to study aspects ofthe disorder being modeled
(Willner 1991).
Regardless of its classification, once a particular animal model is selected for a
disorder, it is necessary to assess its validity. The validity is the degree of confidence that
can be placed in the data generated from the use ofthe model. Three validity measures
are required to fully assess a model. The predictive validity is whether the model is able
to discriminate efficiently between those agents that are clinically effective and those that
are not. Face validity refers to a strong phenomenological association between the model
and the disorder it simulates. The model should resemble the disorder in etiology,
symptomology, treatment, and physiological basis. Since face validity is not always
achievable, a more important measure is construct validity, the final measure of validity.
Construct validity basically refers to a model being able to measure a fundamental
theoretical concept. All valid models are required to have both predictive and construct
validity (Willner 1991).
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Within the subject of anxiety, four main categories of animal models exist. The
first category is that of conditioned avoidance responses, which includes the four-plate
test, passive and active avoidance, and the Geller-Seifter conflict test. These tests mainly
involve mild aversive stimuli to form conditioned responses. For example, many
procedures “use the aversive effects offootshock to condition the inhibition of normally
ongoing behavior; it is hypothesized that the inhibition of behavior in anticipation of
punishment is mediated by the hypothetical construct ‘fear’ or ‘anxiety’, and that such
inhibition should be reduced by anxiolytic treatments”(Willner 1991). A second
category of animal model is the drug-induced discriminative states. In many ways, these
models represent the closest approximation to a bioassay model that can be found in
anxiolytic psychopharmacology. A third model is that of brain stimulation. This
involves the stimulation of many different sites that can produce behavioral indications of
fear in animals such as the amygdala, the locus coeruleus, or the median raphe nucleus.
The final category of animal models, and the category of particular interest in this study,
is the unconditioned response tests. Many ofthe unconditioned response tests involve
exploratory locomotion in a novel environment as a simulation of an anxiety-like state.
However, this category also includes observation ofsocial interactions or aggression and
how these actions relate to anxiety (Willner 1991).
One particular unconditioned response is isolation-induced vocalizations that are
emitted by infants of various species following separation from their mother or
conspecifics. Several studies have identified these responses in guinea-pigs, chicks, and
in rats and mice, in which case ultrasonic vocalizations are recorded (Borsini, 2002). In
particular, the psychopharmacology laboratory at the University of Mississippi has
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worked with chicks and developed the Chick Separation Stress Paradigm(CSSP)as a
model of anxiety. In particular, over the past decade, this lab has developed the CSSP as
an anxiolytic screening model. This paradigm is based upon the fact that, when separated
from their conspecifics, young domestic fowl exhibit a stress response that is
characterized by distress vocalizations(DVocs: Gallup and Saurez, 1980; Panksepp et al.
1980; Sufka and Weed 1994). Through several studies, this laboratory has developed a
method to use DVocs to index anxiety (Watson and Sufka, 1996; Feltenstein et al. 2004,
Feltenstein et al. 2003; Feltenstein et al. 2002). The model possesses construct validity as
an anxiety model in that separation stress reliably increases corticosterone levels
(Feltenstein et al. 2002), a neuroendocrine marker of many stress responses.
Additionally, the model possesses predictive validity through the successful detection of
diverse classes of anxiolytics (i.e., meprobamate, pentobarbital, chlordiazepoxide,
imipramine and clonidine; Feltenstein et al. 2004). Furthermore, the model is insensitive
to a wide range of non-anxiolytic compounds (i.e. amphetamine, scopolamine, caffeine,
chlorpromazine, and haloperidol; Feltenstein et al. 2004).
One problem with the CSSP does arise in the form ofthe atypical anxiolytic
buspirone. Buspirone is a clinically efficacious anxiolytic in humans(Ninan and
Muntasser, 2004). However, in the CSSP,as well as in several other models of anxiety,
buspirone was shown to be ineffective as an anxiolytic (Feltenstein et al. 2004; Stephens
and Andrews 1991). Although this seems a limitation of tlie paradigm, the buspirone
effect may be empirical data that further defines how to classify the model.
Anxiety disorders comprise a large number of disorders where the primary feature
is abnormal or inappropriate anxiety. Two primary anxiety disorders are generalized
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anxiety disorder(GAD)and panic disorder(PD). The etiology of GAD is to have
excessive anxiety and worry, for more days than not, that are out of proportion to the
likelihood or impact of feared events. Symptoms include heart palpitations, muscle
tension, exaggerated startle response, and insomnia. On the other hand, with PD the
patient has recurrent unexpected panic attacks which are followed by a month or more of
persistent concern about having additional attacks. Panic attacks are sudden attacks of
intense fear or discomfort with heart palpitations, sensations of shortness of breath, and
dizziness(Pincus 1995). There has been precedence to qualifying animal models based
on disorder. In a recent international conference on the PD/GAD differentiation, ...most
participants agreed that generalized anxiety and panic disorder are different on the basis
of clinical manifestations, drug response and animal model. ...It is also common
knowledge that existing animal models generate different types offear/anxiety.
(Andreatini et al. 2001). Of particular interest in the current study is to understand the
differential efficacy of buspirone in each of these disorders. Studies have shown
buspirone to be limited to GAD and ineffective for panic disorder and other anxiety
disorders(Ninan and Muntasser, 2004; Bandelow 2002; Sheeham et al. 1990).
The ineffectiveness of buspirone in the CSSP is therefore a key aspect that points
towards the paradigm better modeling PD. Additionally, the CSSP appears to have face
validity in that it bears many similarities to situationally-bound or cued PD since the
symptom onset is rapid, intense and brief with clear etiological origins. It is, therefore,
hypothesized that the CSSP is a better screening assay for anti-panic medications than
for anti-anxiety medications in general.
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In order to dissociate the specific anxiety disorder modeled in the CSSP,the
following strategy was derived. If the CSSP is a model ofPD,then it should only be
sensitive to pharmacological compounds efficacious for PD and insensitive to drugs only
effective for other types of anxiety disorders (e.g., GAD). Therefore, seven drug probes
were chosen as agents to help with this differentiation. Phenelzine was first chosen, since
it is only effective in the treatment ofPD (Bandelow et al. 2002; Davidson 2004). It was
then decided to select three additional drugs that are effective in PD: alprazolam,
clonidine, and imipramine (Bandelow et al. 2002; Hoehn-Saric et al. 1981). These three
medications, while shown to be more highly effective in the treatment ofPD,are also
effective in the treatment of GAD. For drugs exclusively effective in the treatment of
GAD,trazodone and buspirone were chosen, since both are effective GAD treatments
that have no effect on PD (Bandelow et al. 2002; Chamey et al. 1986). The final drug
probe chosen was yohimbine which has been shown to exacerbate symptoms ofPD in
humans(Chamey et al. 1992). It is expected, therefore, to increase DVocs if the CSSP
models PD.
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Materials and Methods

Subjects
Cockerels {Gallus gallus\ strain W36; Cal-Maine Foods, Mendenhall, MS,USA)
were obtained 1 -day post-hatch and were housed in stainless-steel cages(34 x 57 x 40
cm)at a population density of 12-14 chicks per cage. Food (Purina Start and Grow, St.
Louis, MO,USA)and water were available ad libitum through 1-quart gravity-fed
feeders and water containers. Room temperature was maintained at 29V1EC,and
overhead fluorescent illumination was maintained on a 12h light-dark cycle. Daily
maintenance was conducted during the first quarter ofthe light cycle.

Apparatus
The six-unit test appciratus contained Plexiglas viewing chambers(25 x 25 x 22
cm)situated in sound-attenuating enclosures. Each unit was illuminated by a 25-W light
bulb and ventilated by an 8-cm-diameter rotary fan(Commonwealth Model FP-108AX
SI). Miniature video cameras(SuperCircuit Model PC47MC)allowed for animal
observation during tests. DVocs were recorded by microphones(Lafayette Instruments
Model 3-675-001) mounted at the ceiling of the Plexiglas chamber and connected to
digital sound-activating relays(Lafayette Instruments Model 63040A, settings. 75 /o
sensitivity and 0.10 s delay) that triggered electromechanical counters (Lafayette
Instruments Model 58004).
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Procedure
Experiments were conducted at 7-days post-hatch. Groups formed a single
factorial design with a hanging control that included two vehicle-control groups in which
chicks were tested in isolation, with or without two mirrors(20 x 20 cm)positioned along
the outside of the Plexiglas side walls, and four drug dose conditions tested under the NoMirror condition.
The drug probes included one compound clinically effective for PD but not GAD
(phenelzine: 3.125,6.25, 12.5, 25.0 mg/kg), three compounds predominantly used for PD
but also show clinical efficacy for GAD (alprazolam: 0.065,0.125,0.25,0.5 mg/kg,
imipramine: 1.0, 3.0, 10.0, 15.0 mg/kg; clonidine: 0.1, 0.15, 0.2, 0.25 mg/kg),two
compound clinically effective for GAD but not PD (buspirone: 2.5, 5.0, 7.5, 10.0 mg/kg;
trazodone: 0.1, 0.3, 1.0, 3.0 mg/kg)and one compound that exacerbates the symptoms of
as
PD but without effect on GAD (yohimbine: 0.1, 0.3, 1.0, 3.0 mg/kg). DMSO served
the vehicle for trazodone and yohimbine. Alprazolam was dissolved in a solution that
consisted of 20.0ml propylene glycol, 5.0ml ethyl alcohol,0.75ml benzyl alcohol, 2.44g
sodium benzoate, and 60.0mg benzoic acid in 24.0ml of distilled water. All other probes
were dissolved in 0.9% physiological saline. Drug doses were selected based on
published work on chicks from this laboratory or fi-om the literature in rodent models of
anxiety (Feltenstein et al. 2004; Feltenstein & Sufka 2005; Graeffet al. 1998; Mason et
al. 1987; Watson et al. 1999).
Vehicle and drug injections were administered IM 15 min before tests. The stress
manipulation involved placing a chick in the observation chamber either in a Mirror
(low-stress) or No-Mirror (high-stress) condition for a 180 sec test period. Dependent
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measures collected during the test session were 1)distress vocalizations(DVocs)and 2)
sleep onset latency (SOL), defined as the latency to adopt a posture in which the chick’s
head is drooping and its eyes are closed. Animals were returned to their home cage
following tests. These procedures were approved by the University of Mississippi
IACUC (Protocol # 05-007)and were conducted in accordance with the principles of
laboratory animal care as detailed in the National Institutes of Health Guide for Care and
Use of Laboratory Animals(Publication No.85-23, revised 1985).
Data were analyzed using /-tests and analysis of variance(ANOVA).Post hoc
analyses were conducted using Fisher’s LSD for DVocs and Mann-Whitney U for SOL.
Percent effect scores were derived using the following formulas: Percent anxiolytic effect
= [1 -(mean DVocs for Drug Dose / mean DVocs for Vehicle/No-Mirror group)] x 100;
Percent sedative effect =[1 -(Mean SOL /180)] x 100.
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Results:
Phenelzine:
The effects of isolation and phenelzine on DVocs are summarized in Figure 1.
Social isolation led to a clear increase in DVocs. Phenelzine, in turn, dose-dependently
attenuated this stress effect. Consistent with these observations, an analysis of the data
demonstrated that the DVocs for the iso-vehicle group were significantly higher than the
mirror-vehicle group. t(33)= 4.5, p < 0.0001. An ANOVA of DVocs across the isophcnclzine groups revealed a significant treatment effect, F(4,76)= 3.35, p < 0.05. Posthoc analyses demonstrated that the mean DVocs for the 25mg/kg phenelzine group

were

significantly lower than the mean DVocs for vehicle-isolated birds, p < 0.01. No other
relevant comparisons reached statistical significance.
Figure 1: The effects of phenelzine on isohition-induccd distress voenlizntions in a 3-min test session.
Phenelzine was delivered IM 15 minutes prior to testing. Values represent mean ± Standard Error of
the Mean (S.E.M.), sample sizes N= 16-18. The gray bar represents the social test condition and the
black bars represent the isolated test condition.
**
Indicates significant attenuation of the stress effect,
* Indicates a significant isolation stress effect,
all P values < 0.05.
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Figure 2: The effects of isolation and phenelzine on sleep onset latency in a 3-min test session.
Phenelzine was administered IM 15 min prior to testing. Values represent mean ± S.E.M.,sample
sizes N = 16-18. The gray bar represents the social test condition and the black bars represent the
isolated test condition.
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1’he effects of isolation and phenelzine on SOL are summarized in Figure 2.
Neither the isolation manipulation nor phenelzine probes affected SOL. An analysis of
these data using a Kruskal-Wallis one-way ANOVA for non-paramelric data lailed to
reveal a statistically significant treatment effect.

Alprazolam:
The effects of isolation and alprazolam on DVocs are summarized in Figure j.
Social isolation led to a clear increase in DVocs. Alprazolam, in turn, dose-dependently
attenuated this stress effect. Consistent with these observations, an analysis of these data
demonstrated that the DVocs for the iso-vehicle group were significantly higher than the
mirror-vehicle group, t(32) = I L7, p < O.OOOL An ANOVA ot DVocs across the iso
alprazolam groups revealed a significant treatment effect. F(4,8l) = 51.0. p < O.OOOL
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Post-hoc analyses demonstrated that the mean DVocs for the 0.5mg/kg, 0.25mg/kg,
0.125mg/kg. and the 0.065mg/kg alprazolam groups were significantly low-er than the
mean DVocs for vehicle-isolated birds, p < 0.0001. No other relevant comparisons
reached statistical siunificance.
The effects of isolation and alprazolam on SOL are summarized in Figure 4. The
isolation manipulation failed to affect SOL. An analysis of these data using a KruskalWallis one-way ANOVA revealed a significant sedative effect H(5)= 77.20, p<0.0001.
Post-hoc analyses demonstrated that the mean SOL for the 0.5mg/kg, 0.25mg/kg, and the
0.125mg/kg alprazolam groups were significantly lower than the mean SOL for the
vehicle-isolated birds p<0.0001. No other relevant comparisons reached statistical
significance.
Figure 3: The effects of alprazolam on isolation-induced distress vocalizations in a 3-min test session.
Alprazolam was delivered IM 15 minutes prior to testing. Values represent mean ± S.E.M.,sample
sizes 15-18. The gray bar represents the social testing condition and the black bars represent the
isolated test condition.
* Indicates a significant isolation stress effect. ** Indicates significant attenuation of the stress effect,
all P values < 0.0001.
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Figure 4: The effects of isolation and four doses of alprazolam on sleep onset latency in a 3-minute
test session. Alprazolam was delivered IM 15 minutes prior to testing. Values represent mean ±
sample sizes 15-18. The gray bar represents the social test condition and the black bars
represent the isolated test condition.
+ Indicates a significant decrease in sleep onset latency, all P values <0.0001.
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Imipramine:
The effects of isolation and imipramine on DVocs are summarized in Figure 5.
Social isolation led to a clear increase in DVocs. Imipramine, in turn, dose-dependently
attenuated this stress effect. Consistent with these observations, an analysis ol these data
demonstrated that the DVocs for the iso-vehicle group were significantly higher than the
mirror group, t(30) = 5.78, p < 0.0001. An ANOVA of DVocs across the iso-imipramme
groups revealed a significant treatment effect, F(4,85) = 28.3, p < 0.0001. Post-hoc
analyses demonstrated that the mean DVocs for the lO.Omg/kg and 15.0mg/kg
imipramine groups was significantly lower than the mean DVocs for vehicle-isolated
birds, p < 0.001. No other relevant comparisons reached statistical significance.
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Figure 5: The effects of imipraniine on isolation-induced distress vocalizations in a 3-mln test
session. Iniipramine was delivered IM 15 minutes prior to testing. Values represent mean ± S.E.M.,
sample size N = 14-18. The gray bar represents the social testing condition and the black bars
represent the isolated test condition.
* Indicates a significant isolation stress effect,
Indicates significant attenuation of the stress effect,
all P values < 0.0001.
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Figure 6: The effects of Isolation and four doses of imipraniine on sleep onset latency in a 3-miniite
test session. Imipraniine was delivered IM 15 minutes prior to testing. Values represent mean ±
S.E.M., sample size N = 14-18. The gray bar represents the social test condition and the black bars
represent the isolated test condition.
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The effects of isolation and imipramine on SOL are summarized in Figure 6. As
evident, both isolation and imipramine failed to affect SOL. An analysis ofthese data
using a Kruskal-Wallis one-way ANOVA failed to reveal a statistically sigmficant
treatment effect.

Clonidine:
The effects of isolation and clonidine on DVocs are summarized in Figure 7.
Social isolation led to a clear increase in DVocs. Clonidine, in turn, dose-dependently
attenuated this stress effect. Consistent with these observations, an analysis of these data
demonstrated that the DVocs for the iso-vehicle group were significantly higher than the
mirror group, t(26)= 11.7, p < 0.0001. An ANOVA of DVocs across the iso-clonidine
groups revealed a significant treatment effect, F(4,71)= 365.4, p < 0.0001. Post-hoc
analyses demonstrated that the mean DVocs for the 0.25mg/kg,0.2mg/kg, 0.15mg/kg,
and the 0.1 mg/kg clonidine groups was significantly lower than the mean DVocs for
vehicle-isolated, p < 0.0001. No other relevant comparisons

reached statistical

significance.
The effects of isolation and clonidine on SOL are summarized in Figure 8. The
isolation manipulation failed to affect SOL. However, clonidine produced a dosedependent decrease in SOL. An analysis ofthese data using

Kruskal-Wallis one-way

ANOVA revealed a significant sedative effect H(5) = 18.20, p<0.0001. Post-hoc
analyses demonstrated that the mean SOL for the 0.2mg/kg and 0.25mg/kg clonidine
groups were significantly lower than the mean SOL for the vehicle-isolated birds
p<0.0001. No other relevant comparisons reached statistical significance.
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Figure 7: The effects of clonidine on isolation-induced distress vocalizations in a 3-min test session.
Clonidine >vas delivered IM 15 minutes prior to testing. Values represent mean ± S.E.M., N = 11-17.
The gray bar represents the social testing condition and the black bars represent the isolated test
condition.
* Indicates a significant isolation stress effect,
all P values < 0.0001.
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Figure 8: The effects of isolation and four doses of clonidine on sleep onset latency in a 3-minute test
session. Clonidine was delivered IM 15 minutes prior to testing. Values represent mean ± S.E.M.,
N = 11-17. The gray bar repi'esents the social test condition and the black bars represent the isolated
test condition,
t Indicates a significant decrease in sleep onset latency, all P values <0.005.
200

160

160

140

t

J2. 120
□ Social

3 100

■ Isolated

a
O
60
in
60

40

20

0
Vehicle

Clonidiiio [0 1 mg/kg)

Clonidine (0 15 mg/kg]

Clonidine (0 2 mg/kg)

Drug Condition

17

Clonidine [0 25 mg/kg]

Buspirone:
I'he effects of isolation and buspirone on DVocs are summarized in Figure 9.
Social isolation led to a clear increase in DVocs. Buspirone, however, failed to attenuate
this stress effect. In fact, buspirone produced an anxiogenic effect in the two higher
doses. Consistent with these obser\'ations, an analysis of these data demonstrated that the
DVocs for the iso-vehicle group were significantly higher than the mirror group, t(:>2)=
3.62, p < 0.001. An ANOVA of DVocs across the iso-buspirone groups revealed a
signi[leant treatment effect. F(4,76)= 4.29, p < 0.005. Post-hoc analyses demonstrated
that the mean DVocs for the 2.5mg/kg and 5.0mg/kg buspirone groups was significantly
higher than the mean DVocs for vehicle-isolated birds, p < 0.05. No other relevant
comparisons reached statistical significance.

11 3-inin test session.
Figure 9: The effects of buspirone on isolation-induced distress vocalizations in
Buspirone was delivered IM 15 minutes prior to testing. Values represent mean ± S.E.M., sample
size N = 14-18. The gray bar represents the social testing condition and the black bars repi esent the
isolated test condition.
* Indicates a significant isolation stress effect. $ Indicates significant increase of this stress effect, all
P values < 0.05.
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The effects of isolation and buspirone on SOL are summarized in Figure 10.
Neither the isolation manipulation nor buspirone probes affected SOL. An analysis of
these data using a ICruskai-Wallis one-way ANOVA failed to reveal a statistically
significant treatment effect.
Figure 10: The effects of isolation and four doses of buspirone on sleep onset latency in a 3-minute
test se.ssion. Buspirone was delivered IM 15 minutes prior to testing. Values represent mean ±
S.E.M., N= 14-18. The gray bar represents the social test condition and the black bars represent the
isolated test condition.
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Trazi)done:
The effects of isolation and trazodone on DVocs are summarized in figure I 1.
Social isolation led to a clear increase in DVocs. Trazodone, however, failed to attenuate
this stress effect. Consistent with these observations, an analysis ol these data
demonstrated that the DVocs for the iso-vehicle group were significantly highei than the
mirror group, t(34) - 13.3, p < 0.0001. An ANOVA of DVocs across the iso-trazodone
groups failed to reveal a significant effect, F(4,83) = 1.80, p < 0.5. No fuithei analyses
were conducted on these data.
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Figu re 11: The effects of trazodone on isolation-induced distress vocalizations in a 3-min test session.
Trazodone was delivered IM 15 minutes prior to testing. Values represent mean ± S.E.M., sample
size N = 16-18. The gray bar represents the social testing condition and the black bars represent the
isolated test condition.
* Indicates a significant isolation stress effect, all P values < 0.05.
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Figure 12: Tlic effects of isolation and four doses of trazodone on sleep onset latency in a 3-minute
test session. Trazodone was delivered IM 15 minutes prior to testing. Values represent mean ±
S.E.IM., sample size N = 16-18. The gray bar represents the social test condition and the black bars
represent the isolated test condition.
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The effects of isolation and trazodone on SOL are summarized in Figure 12. As
evident, both isolation and trazodone failed to affect SOL. An analysis ofthese data
using a Kruskal-Wallis one-way ANOVA failed to reveal a statistically significant
treatment effect.

Yohimbine:
The effects of isolation and yohimbine on DVocs are summarized in Figure 1j.
Social isolation led to a clear increase in DVocs. Yohimbine, however,failed to
this stress effect. In fact, yohimbine attenuated the stress

effect at three ofthe four doses.

Consistent with these observations, an analysis ofthese data demonstrated t
,t(33)= 7.21,p
for the iso-vehicle group were significantly higher than the mirror group
< 0.0001. An ANOVA of DVocs across the iso-yohimbine groups

revealed a significant
the mean DVocs for

effect, F(4,81)= 3.27, p < 0.05. Post-hoc analyses demonstrated that
mean DVocs for vehiclethe 3.0mg/kg yohimbine group was significantly lower than the
isolated birds, p < 0.05. No other relevant comparisons reached statistical sig
mmarized in Figure 14.
The effects of isolation and yohimbine on SOL are su
SOL. An analysis of
Neither the isolation manipulation nor phenelzine probes affected
these data using a Kruskal-Wallis one-way ANOVA failed to reveal a statistically
significant treatment effect.

21

Figure 13: The effects of yohimbine on isolation-induced distress vocalizations in a 3-min test
session. Yohimbine was delivered IM 15 minutes prior to testing. Values represent mean ± S.E.M.,
sample size N = 16-18. The gray bar represents the social testing condition and the black bars
represent the isolated test condition.
"k if
* Indicates a significant isolation stress effect,
Indicates significant attenuation of the stress effect,
all P values < 0.05.
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Figure 14: The effects of isolation and four doses of yohimbine on sleep onset latency in a 3-minute
test session. Yohimbine >vas delivered IM 15 minutes prior to testing. Values represent mean ±
S.E.iVl., sample size N = 16-18. The gray bar represents the social test condition and the black bars
represent the isolated test condition.
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To compare the relative effects of these drug probes on the two dependent
measures, DVoc and SOL scores were converted to percent anxiolytic and sedative effect
scores, respectively, and these data are summarized in Table 1. Although no inferential
statistics were performed on these percent effect scores, in the cases where alprazolam
and clonidine produced both significant anxiolytic and sedative effects, the anxiolytic
effect was more pronounced at a given dose and/or occurred at a lower dose. This pattern
of results argues that the anxiolytic effects ofthese compounds are not a confound of
general sedation.
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Table 1: Percent Anxiolytic and Sedative Effects of Drug Probes. Distress Vocalizations(DVoc),
Sleep Onset Latency(SOL),* = significant isolation-stress effect, ** = significant anxiolytic effect,$ =
significant anxiogenic effect,f = significant sedative effect, all p® < 0.05.

Dose 1

Dose 2

Dose 3

Dose 4

Phenelzine
DVoc
SOL

-.2.34
0.00

1.62
0.00

18.43
0.00

32.47 **
0.00

A Iprazolam
DVoc
SOL

72.22 **
22.28 t

88.54
62.28 t

99.25 **
97.56 t

99.79
100.00 t

Imipramine
DVoc
SOL

-11.52
0.00

13.35
0.00

35.15
0.00

88.73 **
0.00

Clonidine
DVoc
SOL

88.96
11.22

99.27
19.61

97.55
37.39 t

100.0
38.83 t

Buspirone
DVoc
SOL

-25.94 t
0.00

-45.61 t
0.00

-9.38
0.00

-13.33
0.00

Trazodone
DVoc
SOL

20.07
3.46

3.56
0.00

15.21
0.00

-0.88
0.00

Yohimbine
DVoc
SOL

17.01 **
0.00

11.41
0.00

14.89 ♦He
0.00

26.04 **
0.00
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Discussion

Previous studies have validated the CSSP as a high-throughput, in vivo screening
assay for anxiolytic compounds (Feltenstein et al. 2004; Feltenstein et al. 2003;
Feltenstein et al. 2002). However, many forms of anxiety exist, each having its own
unique characteristics. Through testing a series of pharmaceuticals used for the treatment
of various forms of anxiety, this study set out to verify which form of anxiety is
simulated by the paradigm. A series ofexperiments was designed to determine whether
the paradigm was a screen for medications used in the treatment of panic disorder(PD)or
generalized anxiety disorder(GAD). Seven known anxiolytic drugs with different
specific treatment characteristics were chosen. One drug, phenelzine, is used exclusively
in the treatment of PD. This would serve to validate the paradigm as a model ofPD.
Alprazolam, clonidine, and imipramine were then chosen to further validate the model,
since they are effective in the treatment of both PD and GAD. Two drugs, trazodone and
buspirone, were chosen as negative controls since they are both effective in GAD but
have no effect in PD. Finally, yohimbine, which is shown to exacerbate symptoms of
panic in humans, was chosen as a final validation ofthe paradigm as a screen for
pharmaceutics used in the treatment ofPD.
As hypothesized, if the CSSP is a model ofPD,then isolation-induced DVocs
should be attenuated both by the compound effective only in the treatment ofPD and by
the compounds effective in the treatment of PD and GAD. Likewise, the isolationinduced DVocs should not be attenuated by the compounds effective only in the
treatment of GAD and should be enhanced by the compound known to exacerbate
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symptoms of PD. but not GAD,in humans.
Seven-day old cockerels were administered intramuscularly either the vehicle or
drug probe 15 minutes prior to the test period. During the testing period, the chicks were
placed in a mirror (low-stress/social simulation) or no-mirror (high-stress/isolation)
condition for 180 sec. During this period, the dependent measures of DVocs and SOL
were recorded to index separation stress and sedation, respectively. The results obtained
were then analyzed statistically to determine significance.
Consistent with previous reports (Feltenstein et al. 2002; Feltenstein et al. 2003;
Feltenstein et al. 2004; Wamick et al. 2005), this study demonstrated that isolation(no
mirror condition) produced a robust increase in DVocs across all experiments. This
response is a direct measure of the amount of stress experienced by the animal
(Feltenstein, 2004). Furthermore, all drug probes effective in PD and the probes effective
in both PD and GAD showed a significant attenuation of this increase without significant
sedative effects.
Phenelzine was chosen as a probe representative of compounds that are
exclusively effective in treatment of PD. As expected, phenelzine produced a dose
dependent decrease in DVocs with a statistically significant decrease at the highest dose,
a finding consistent with previous observations in this paradigm (Feltenstein 2005). No
sedative effect was identified. This pattern of data argues that minimally the paradigm
better simulates PD than GAD.
Similar positive results were seen in the three drug probes that have been shown
to be effective in both PD and GAD: alprazolam, clonidine, and imipramine. All tliree
probes showed statistically significant attenuation of DVocs, without sedation.
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Significant effects on SOL were seen with both alprazolam and clonidine. However,in
both cases the anxiolytic properties were more pronounced at a given dose and/or
occurred at a lower dose, evidence that the anxiolytic effects ofthese compounds were
not confounded by sedation. Furthermore, the relative efficacy and potency ofthe test
compounds in the chick model were shown to be liighly similar to the human clinical
efficacy found in PD. In the chick paradigm, both clonidine and alprazolam were much
more efficacious than imipramine, which in turn was more efficacious than phenelzine.
This pattern exactly mirrors the one found in human clinical studies(Chamey et al. 1986;
Davidson and Connor, 2004).
In the case of trazodone and buspirone, the two drug probes shown to be clinically
effective in GAD but not PD, no statistically significant attenuation of DVocs was
revealed. These results are consistent with the hypothesis that the chick separation
paradigm more closely models PD than GAD. It should be noted, however, that a
significant anxiogenic effect was recorded for the two lower doses of buspirone.
Although unexpected, the buspirone results are consistent with those in previous studies
involving the CSSP (Feltenstein 2005).
While the failure of buspirone to attenuate DVocs supports the model as
representative of PD,chronic administration of buspirone is often required for human
clinical efficacy (Ninan and Muntasser 2004). However,four main reasons serve to
explain why acute administration of buspirone was used in this study. First, other animal
models have detected buspirone’s anxiolytic effects after acute administration (e.g.. Cole
and Rodgers 1994). Second, the CSSP was able to detect the anxiolytic effects of other
drugs that nonnally require chronic administration for therapeutic effects (i.e..
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imipramine and phenelzine). Third, it has been argued that successful in vivo
pharmacological screens should be capable of screening drugs solely on acute
administration (Willner 1991). And finally, human studies have shown that due to the
method of administration, intramuscular injection, compounds that usually require
chronic administration when given orally display acute effects when injected (Becker
1971).
Taken together, the effects of these drug probes reveal a pattern that is consistent
with the hypothesis that the CSSP is a better simulation ofPD than GAD. On the other
hand, the final drug probe, yohimbine, gave rather indeterminate results. While
yohimbine failed to exacerbate DVocs,it did reveal a statistically significant attenuation
at the first dose and the two higher doses. These results are neither exemplary of a model
of PD, in which case DVocs should have been attenuated, or GAD,in which case no
statistically significant effect should have been recorded. These unexpected results are
further thrown into question by the fact that yohimbine, an V2 antagonist, failed to
exacerbate DVocs while clonidine, an V2 agonist, attenuated them. Although yohimbine
has been shown to increase the symptoms ofPD in humans(Chamey et al. 1989), the
modest anxiolytic effect of yohimbine detected in this study should not be surprising as
this drug has been shown to attenuate stress behaviors in other animal models (e.g.,
punished drinking assay, Baldwin et al, 1989; Gower an Tricklebank 1988; conditioned
ultrasonic DVocs, Molewijk et al. 1995; De Vry et al. 1993).
One might argue that the failure of yohimbine to exacerbate DVocs is a limitation
to this paradigm as a valid simulation of PD. However,the lack of a stereotypical
yohimbine effect should not be considered a fatal flaw when the model is being used as a
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pharmacological screen. The primary importance of a screening assay is on its ability to
successfully screen clinically active compounds without producing false negatives and, to
a lesser degree, false positives(Willner 1991). False positives, as exemplified by
yohimbine in this study, will be detected in subsequent screenings and never enter into
clinical trials.
The results of this study serve to further validate the CSSP as a pharmacological
screening assay for anxiolytics effective in tlie treatment ofPD. As stated above, the
CSSP has been used extensively in this lab and has been shown to be a valid model of
anxiety (Fellenstein et al., 2004). Although some rodent based models of anxiety do
exist, they tend to be time consuming, involve more stress for the animal, and are
expensive. This test uses one testing period of three-minute duration whereas many
rodent models require multiple trials and longer tests, placing more stress on the animal.
Also, the chick separation stress model is highly cost-effective,which is illustrated by
comparing purchase cost between rats and chicks; 1 rat = 110 chicks. Per Diem expenses
are also less in the chick model. Furthermore, the CSSP is unique in that it meets the
National Institutes of Health’s 3R policy to Reduce, Refine, and Replace (Office of
Laboratory Animal Welfare, 2002). The model reduces the number of purpose-bred
research animals since the male chicks used in this experiment are a by-product ofthe
commercial egg-laying industry (i.e., cockerels are discarded at hatch; Roach and Sufka,
2003). The screen has also refined the procedure since, as afore mentioned, it minimizes
the stress-provoking stimuli to a single, short 3-minute test session. Finally, the screen
replaces the standard rodent-based screening procedures for anxiolytics with a
phylogenetically lower and less sentient species. These attributes strongly suggest the
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adoption of the CSSP as an early preclinical screening assay for anxiolytics for the
treatment of PD.
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Appendix

Table 2: Effects of Drug Probes on Isolation-induced Distress Vocalizations(DVocs)
and Sleep Onset Latency(SOL)

Treatment
Phenelzine
Vehicle/mirror
V eh ic1 e/no-m i rror

18
17

DVoc
Mean(SEM)

SOL
Mean(SEM)

97.0(23.3)
235.9(19.8)*

180.0(0.0)
180.0(0.0)

34

3.125 mg/kg
6.25mg/kg
12.5 mg/kg
25.0mu/ku
Alprazolam
Vehicle/mirror
Vehicle/no-mirror
0.065mg/kg
0.125mg/kg
0.25mg/kg
0.5 mg/kg
Imipramine
Vehicle/mirror
Vehicle/no-mirror
1.Omg/kg
3.0mg/kg
10.Omg/kg
15.Omg/kg
Clonicline
Vehicle/mirror
Vehicle/no-mirror
0.1 mg/kg
0.15 mg/kg
0.2mg/kg
0.25mg/kg
Buspirone
Vehicle/mirror
Vehicle/no-mirror
2.5mg/kg
5.Omg/kg
7.5 mg/kg
10.Omg/kg
Trazodone
Vehicle/mirror
Vehicle/no-mirror
0.1 mg/kg
0.3 mg/kg
1.Omg/kg
3.Omg/kg

16
15
16
17

241.4(11.5)
231.1 (21.6)
192.4(21.9)
159.3(21.0)

180.0(0.0)
180.0(0.0)
180.0(0.0)
180.0(0.0)

16
18
17
15
18
18

11.1(5.7)
186.8(13.2)*
51.9(15.8)
21.4(15.7)
1.4(0.7)
0.4(0.2)

180.0(0.0)
180.0(0.0)
139.9(14.3)t
67.9(14.2)t
4.4(4.4)t
0.0(0.0)t

13
18
17
16
18
18

28.2(16.6)
226.5 (23.2)*
252.6(10.9)
218.9(22.0)
141.9(20.1)
16.0(4.8)

180.0(0.0)
180.0(0.0
180.0(0.0)
180.0(0.0)
180.0(0.0)
180.0(0.0)

18
13
18
18
18
18

31.8(11.7)
192.5(19.4)*
25.1 (14.0)
1.4 (1.2)
4.7(3.7)
0.0(0.0)

180(0.0)
180.0(0.0)
159.8(10.1)
144.7(11.4)
112.7(15.1) t
110.1 (16.3)t

17
17
15
14
17
18

110.41 (21.1)
219.5 (21.5)*
276.46(13.0) t
319.571 (16.1) t
240.1 (18.4)
248.7(18.0)

180.0(0.0)
180.0(0.0)
180.0(0.0)
180.0(0.0)
180.0(0.0)
180.0(0.0)

18
18
18
16
17
16

17.3 (9.6)
238.7(13.6)*
190.8 (21.6)
230.2(18.3)
202.4(20.7)
240.8(11.2)

180.0(0.0)
180.0(0.0)
173.8(6.2)
180.0(0.0)
180.0(0.0)
180.0(0.0)
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Yohimbine
Vehicle/mirror
Vehicle/no-mirror
0.1 mg/kg
0.3mg/kg
1.Omg/kg
3.0mg/kg

18
17
16
18
18
17

82.3 (21.2)
259.2(11.5)*
215.1 (18.6)
229.6(9.1)
220.6(11.7)
191.7(15.5)

180.0(0.0)
180.0(0.0)
180.0(0.0)
180.0(0.0)
180.0(0.0)
180.0(0.0)

* = significant isolation-stress effect, = significant anxiolytic effect, J = significant
anxiogenic effect, t = significant sedative effect, all < .05.
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Table 3: Comparative activity of drug probes in clinical cases of panic disorder
(PD), generalized anxiet>' disorder(GAD),and in the chick separation stress
paradigm.
Effect in the Chick
Drug Probe
Phenelzine

Effect in
PD

Effect in
GAD

Separation Stress
Paradigm

+

Alprazolam

+

+

Imipramine

+

+

Clonidine

+

+

Buspirone

4-

Trazodone

+

+ = anxiolytic activity, - = absence of anxiolytic activity.
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